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Abstract 
Randomised trials are at the heart of evidence-based healthcare, but the methods and 
infrastructure for conducting these sometimes complex studies are largely evidence free. Trial 
Forge (www.trialforge.org) is an initiative that aims to increase the evidence base for trial 
decision making and, in doing so, to improve trial efficiency. 
This paper summarises a one-day workshop held in Edinburgh on 10 July 2014 to discuss 
Trial Forge and how to advance this initiative. We first outline the problem of inefficiency in 
randomised trials and go on to describe Trial Forge. We present participants’ views on the 
processes in the life of a randomised trial that should be covered by Trial Forge. 
General support existed at the workshop for the Trial Forge approach to increase the evidence 
base for making randomised trial decisions and for improving trial efficiency. Agreed upon 
key processes included choosing the right research question; logistical planning for delivery, 
training of staff, recruitment, and retention; data management and dissemination; and close 
down. The process of linking to existing initiatives where possible was considered crucial. 
Trial Forge will not be a guideline or a checklist but a ‘go to’ website for research on 
randomised trials methods, with a linked programme of applied methodology research, 
coupled to an effective evidence-dissemination process. Moreover, it will support an informal 
network of interested trialists who meet virtually (online) and occasionally in person to build 
capacity and knowledge in the design and conduct of efficient randomised trials. 
Some of the resources invested in randomised trials are wasted because of limited evidence 
upon which to base many aspects of design, conduct, analysis, and reporting of clinical trials. 
Trial Forge will help to address this lack of evidence. 
Keywords 
Randomised controlled trials, methodology, efficiency, research waste 
Background 
‘There is a peculiar paradox that exists in trial execution - we perform clinical 
trials to generate evidence to improve patient outcomes; however, we conduct 
clinical trials like anecdotal medicine: (1) we do what we think works; (2) we 
rely on experience and judgement and (3) limited data to support best 
practices.’ 
Monica Shah, quoted in Gheorghiade et al. [1]. 
This paper summarises a one-day workshop held in Edinburgh on 10 July 2014 to discuss 
Trial Forge (www.trialforge.org), an initiative focused on improving randomised trial 
efficiency and quality. The initiative is aimed at the people who design and run trials, staff at 
trials units, for example, or clinicians and others who design studies. In this paper, we outline 
the problem of inefficiency in trials and describe the Trial Forge initiative to improve 
efficiency. We hope that many of those reading the paper will be interested in contributing to 
Trial Forge in the future. 
Randomised trials (hereafter ‘trials’), especially when brought together in systematic reviews, 
are regarded as the gold standard for evaluating the effects of healthcare treatments, with 
thousands of trials and hundreds of systematic reviews reported every year. PubMed has 
indexed over 370,000 reports of randomised trials; the World Health Organisation’s 
International Clinical Trials Registry Platform [2] contains over 250,000 trial records, of 
which, 71,000 are listed as recruiting; and the Cochrane Central Register of Controlled Trials 
contains more than 800,000 records. Tens of billions of dollars of public and private money 
are invested globally in trials every year (US $25 billion in the United States alone in 2010 
[3]) and the average cost of a trial per participant is estimated to be almost £8,500 in the 
United Kingdom [4]. 
Many of these resource are wasted, often because insufficient account is taken of existing 
evidence when choosing questions to address [5], and results are either not published or 
poorly reported. Moreover, despite trials being a cornerstone of evidence-based healthcare, 
the methods and infrastructure for conducting these complex studies are largely evidence free 
[6]. For example, every trial has to recruit and retain participants, but only a handful of 
recruitment and retention strategies and interventions are currently supported by high-quality 
evidence [7, 8]. A recent analysis found that only 55 % of UK National Institute of Health 
Research and Medical Research Council (MRC) trials (a set of large, relatively well-funded 
studies in the UK) recruiting between 2002 and 2008 met their recruitment targets [9]. The 
same study found that extensions are common, with 45 % of trials needing at least one 
funding extension, although only 55 % of these then go on to meet their recruitment targets. 
Furthermore, although data collection is central to trials and can consume a large proportion 
of trial resources, researchers often collect more data than they are able to analyse and 
publish [10]. Indeed, there is a dearth of research into the optimal methods for data collection 
and data management [11]. This is a different problem from selective reporting, where bias is 
introduced through the way outcomes are selected and presented in trial reports, especially 
for harms [12]. Vera-Badillo and colleagues called this type of bias ‘spin’ [13]. 
As a consequence, the most appropriate methods are not always chosen when trials are 
designed, leading to trial management and delivery problems later. Indeed, poor design 
decisions may do more than make a trial difficult to deliver; they may mean that any eventual 
findings will be of limited value. This could be because, for example, the comparator used 
renders the trial clinically irrelevant [14], the outcome measures are not relevant to those 
making treatment decisions [15], or the patients involved do not represent the majority of 
patients with the condition of interest [16]. The patients, health professionals, and 
policymakers who look to systematic reviews of trials for help in their decision making are 
often frustrated to find that the questions addressed by researchers do not reflect clinical 
decision making needs (a failure of prioritisation) [17], have dubious relevance in their 
settings [17–19], or that failings in the conduct or reporting of trials mean that they do not 
provide the reliable and robust evidence that they need. Some trials may simply be 
unnecessary [20]. This all represents an unacceptably wasteful approach to designing, 
running, analysing, and reporting trials. The problem of inefficiency in medical research is 
not new: Schwartz and Lellouch urged trialists to change the way they designed trials as long 
ago as 1967 [21], Altman pointed to the scandal of poor medical research in 1994 [22], and, 
in 2009 [23], Chalmers and Glasziou estimated that more than 85 % of the resources invested 
in medical research was being avoidably wasted. What has been lacking is a coordinated 
attempt to tackle inefficiency in clinical trials. 
Main text 
Trial Forge 
Trial Forge (www.trialforge.org) aims to address the lack of an accessible evidence base 
around trial efficiency and quality. A one-day workshop, funded by the Network of MRC 
Hubs for Trials Methodology Research and the Health Services Research Unit at the 
University of Aberdeen, UK, was held in Edinburgh on 10 July 2014 to discuss the initiative. 
The grant holders of the MRC Hub funding (Marion Campbell, Mike Clarke, Athene Lane, 
Trudie Lang, John Norrie, Shaun Treweek, and Paula Williamson) invited 38 participants 
with experience in methodology and trial design, trial management, statistics, data 
management, clinical care, commissioning and publishing research, public and patient 
involvement, and providing trial support through trials units to the worship. 
The aims of the workshop were as follows: 
1. To share knowledge on resources that already exist with regard to efficient trials. 
2. To share knowledge on guidance relating to trial design, conduct, analysis, and reporting. 
3. 
To agree on the key processes of the trial pathway, that is, the major processes in the life 
of a trial. 
4. To begin to suggest features that Trial Forge must have. 
5. To promote awareness of Trial Forge. 
6. To produce a statement paper on the Trial Forge initiative 
As the workshop members were professional trialists, trial managers, statisticians, and others 
involved in trial design, conduct, analysis, and reporting and the discussions were of current 
practice, no formal ethics approval, or consent was deemed necessary. 
How will Trial Forge work? 
Discussion at the workshop highlighted several substantial problems, some of which are 
listed in Table 1. Trial Forge aims to remove or reduce these problems and others through 
targeted collaborative work. Some of the ways it will do this are listed in Table 1. Trial Forge 
will use a five-step process to identify and address gaps in knowledge about trial method: 
Table 1 Trial Forge Examples of trial challenges and how Trial Forge could help 
General problem Examples Examples of how Trial Forge aims to help 
Information is spread over 
many journals, websites, books 
and other publications, which 
makes it difficult to access and 
use in decision making. This 
makes finding and navigating 
the literature time-consuming 
and challenging. 
Searching Pubmed 
[http://www.ncbi.nlm.nih.gov/sites/entrez/, searched 2 Jan 
2015] using the phrase clinical trial recruitment and limiting 
to reviews in the last 5 years produces 252 hits, too large a 
number to sift through easily. 
To collate, or link people to, existing high-
quality evidence on key trial processes. For 
recruitment this would include: what 
influences recruitment strategies that can 
improve recruitment how to tailor recruitment 
strategies to particular contexts 
A search on Google Scholar [http://scholar.google.com, 
searched 2 Jan 2015] using the same phrase (exact phrase 
search) produces 1080 hits since 2010. 
To develop targeted research agendas 
designed to fill gaps in knowledge around 
how best to recruit trial participants. 
Searching Amazon [http://www.amazon.co.uk searched 2 
Jan 2015] for clinical trial recruitment produces 525 hits; 
the first page results of includes books costing less than £1 
to over £900. 
To make it easier for teams to work together 
to address these research agendas. 
In the absence of high-quality evidence, 
provide a repository for the experience and 
knowledge from the community of trialists as 
to how they recruit participants. 
There are substantial gaps in the 
evidence base for key issues 
that affect all trials and which 
are not being systematically 
targeted by methodology 
research. 
There is little published research evidence to inform 
decisions about trial management options such as how best 
to select clinical sites, how to maintain relationships with 
sites, how to model the movement of patients and staff 
through trial processes, or how to effectively train trial and 
site staff. 
To develop targeted research agendas 
designed to fill gaps in knowledge about how 
to design, run, analyse and report trials. 
For trial management, the development of 
methods to allow trial managers to share their 
solutions without the need for full 
publications, which are not generally part of 
the career development of trial managers (ie. 
there is no incentive to publish). 
Encourage systematic reviewers (eg. of 
Cochrane reviews) to suggest concrete 
methodological studies that need to be done 
and to link these to initiatives such as SWATs 
[43, 44] to provide ready-made protocols for 
those studies. 
Systematically direct information about 
evidence gaps to funding agencies for their 
consideration as part of their prioritisation 
process for the selection of topics for funding 
calls. 
Much trial knowledge is tacit 
and held by experienced staff 
working at trials units, other 
similar centres, or on individual 
trials. 
Although many research groups and units cost, manage and 
create data management systems for trials, there is little 
easily available information on effective ways of how to 
complete each of these processes. 
In the absence of high-quality evidence, 
provide a repository for the experience and 
knowledge from the community of trialists as 
to how they design, run, analyse and report 
their trials. 
Collate and evaluate tools that are being used 
by groups designing and running trials such as 
trials units and other similar centres. 
To develop targeted research agendas 
designed to move from tacit, often 
unevaluated knowledge, to high-quality 
evaluated evidence. 
There is no easy way for 
individuals needing advice to 
access it from the potentially 
thousands of people who have 
If a trial data management team using the OpenClinica 
system encounters a technical problem, there is an active 
online community that provides help free 
(https://community.openclinica.com). Questions are 
Provide a repository for the experience and 
knowledge from the community of trialists as 
to how they design, run, analyse and report 
their trials. 
knowledge that might help 
them. 
answered quickly. There are few similar opportunities to 
quickly address questions on trial design, conduct, analysis 
or reporting. 
Provide support for electronically linked 
communities of practice (e.g. through 
Question & Answer and discussion sections 
on its website) 
Learn from The Global Health Network 
(https://tghn.org) on how to build online 
communities in healthcare. 
Information is not structured in 
a way that helps people find 
what they need to resolve their 
uncertainties. People working 
on trials have questions (such as 
‘Should I visit the sites to boost 
recruitment?’, ‘How much 
quality assurance do I need to 
do?’, ‘Will adding an extra 
outcome measure affect 
recruitment and retention?’), but 
guidance is rarely organised 
around questions and the 
answers to them. 
The Clinical Trials Toolkit (http://www.ct-
toolkit.ac.uk/routemap) provides regulatory and other 
information about drug trials in the UK Although useful, the 
information is structured like a text book. People visiting the 
site, however, are likely to have done so because they have a 
series of questions about their trial and are looking for 
answers. The textbook structure makes answering these 
questions slower than it could be. 
Provide a mixed structure to Trial Forge, 
where much of the material is directly framed 
as questions and answers. Where evidence 
provides a clear answer, this information will 
be presented as a question. 
Work with trialists to present information in 
such a way that it enables them to find 
answers to their questions as quickly as 
possible. 
There is no easy way to support 
collaborative, trial methodology 
research to address evidence 
gaps and shortcomings. 
The 2010 Cochrane review of interventions to improve trial 
recruitment [7] includes 45 trials evaluating 46 
interventions. Despite this, the review concludes that there is 
high-quality evidence supporting only three or so 
interventions. The effectiveness or otherwise of the other 
interventions remains unclear. 
The initiatives listed above will help to 
identify gaps in evidence. Trial Forge will 
then highlight these, including to funders in 
an effort to focus researcher effort on 
important and known gaps. 
By supporting SWATs [43, 44], researchers 
wishing to fill at least some of these gaps will 
be able to use existing (and common) 
protocols to evaluate given interventions. 
Provide electronically linked communities 
that can agree to work together to fill a gap 
by, for example, evaluating the same 
intervention across many trials. A good 
example of this approach is the MRC START 
project for recruitment interventions: 
http://www.population-
health.manchester.ac.uk/mrcstart/ 
1. Identify trial processes 
2. Collate what is known about these processes. 
3. Strengthen the evidence base by creating a methodology research agenda. 
4. Collaborate to work through the methodology research agenda. 
5. Dissemination. 
Step 1 - Identify trial processes 
Step 1 will identify the processes that make up a trial, starting with the main processes (for 
example, recruitment) and then breaking these down into smaller processes (for example, 
how to set the eligibility criteria for a trial, selecting the components of the recruitment 
strategy, identifying potential participants, and targeting appropriate recruitment strategies for 
them). This is similar to the process improvement approach taken by the British cycling team 
in its preparation for the 2012 London Olympic Games. Dave Brailsford, British Cycling's 
Performance Director at the time said when asked about the team’s approach: 
‘The whole principle came from the idea that if you broke down everything 
you could think of that goes into riding a bike, and then improved it by 1 %, 
you will get a significant increase when you put them all together.’ [24] 
There are very many processes involved in a trial, and learning about, and improving each of 
them may have a minimal effect on its own, but taken together, these improvements could 
have a much more profound impact. 
Participants at the Edinburgh workshop produced an initial list of headline trial processes 
(Fig. 1) for which collating (and creating) research evidence would be beneficial. This list 
will form the starting point for Trial Forge work. 
Fig. 1 Key processes of the trial pathway (many of which are overlapping and non-linear). 
Suggestions from a one-day workshop held in Edinburgh on 10 July 2014. The placement 
and length of the bars gives an indication of when in the trial they start and end, though this is 
likely to vary greatly between trials 
Step 2 - Collate what is known about these processes 
In Step 2, Trial Forge will either identify existing initiatives to collate what is known about 
individual processes or work to collate the evidence (which may include providing links to 
ongoing studies) and integrate reviews (and other relevant literature) using both quantitative 
and qualitative synthesis approaches [25–28]. For example, for help in choosing trial 
outcomes, Trial Forge would direct people towards the COMET (Core Outcome Measures in 
Effectiveness Trials [29], http://www.comet-initiative.org) Initiative. COMET has 
systematically reviewed published standardised core outcome sets for trials [30], and 
combined these in the COMET database with information on core outcome sets currently 
being developed. As another example, for help with choosing evidence-based recruitment 
interventions, the MRC Network of Hubs for Trials Methodology Research is funding a 
project to develop a searchable database containing published and ongoing research into 
recruitment. On a smaller scale, Cochrane Methodology Reviews, and other systematic 
reviews have brought together existing research in specific topic areas. These will be 
highlighted in Step 2. Epistemonikos (http://www.epistemonikos.org/en/), a website that links 
together systematic reviews, overviews of reviews, and primary studies to support health-
policy decisions, is another example of how research evidence can be collated. 
More generally, the Evidence-Based Research Network (http://www.ebrnetwork.org) is an 
example of an initiative that aims to promote the efficient use of existing research, especially 
through the use of systematic reviews [31] and information about ongoing research. 
Proposals for new research should be informed by systematic reviews, and reports of new 
research should be set in the context of updated systematic reviews. 
Trial Forge will aim to apply quality criteria when pointing to external resources and when 
collating individual studies. How to do this will form part of the initial work of Trial Forge, 
though it is likely that GRADE [32] (a system for grading the quality of evidence and the 
strength of recommendations, particularly for guidelines) will contribute importantly. 
Different approaches to presenting evidence will be explored using methods developed by the 
GRADE Working Group where appropriate, and the methods used to present the information 
will be informed by work done with, among others, the Cochrane Plain Language Summaries 
[33], the GRADE Summary of Findings tables [34, 35], and the DECIDE project (a project 
that aims to improve the way research information is presented in guidelines, 
http://www.decide-collaboration.eu). This presentation work will also be evaluated. 
Step 3 - Strengthen the evidence base by creating a methodology research 
agenda 
Step 3 will focus on strengthening the evidence base by providing a platform to highlight key 
areas of uncertainty, which would enable individuals and research groups to suggest ways in 
which the uncertainties could be addressed. For example, we know less about the effect of 
recruitment interventions aimed at recruiters than we do about those aimed at potential 
participants [7]. Recruiters play a hugely influential role and can have a substantial impact on 
recruitment [36, 37], but there remains uncertainty about how best to address the issues and 
concerns that recruiters face [36–45]. One way to help fill this gap (and others) may be 
through the availability of standard outlines for Studies Within A Trial (SWATs). The design 
of SWAT-1 is for site visits by the principal investigator to increase or maintain recruitment 
[46]. 
Publishing protocols for methodology research, which can then be embedded in other studies, 
makes it easier for research groups to become involved in filling evidence gaps. Much of the 
intellectual work around the appropriate methodology research already will have been done 
by the authors of the protocol. A database of outlines for SWATs is being developed to 
improve access to these ideas [47]. Step 3 of Trial Forge will produce SWATs as well as link 
people to initiatives such as the MRC-funded Systematic Techniques for Assisting 
Recruitment to Trials (START) programme (http://www.population-
health.manchester.ac.uk/mrcstart/), which is developing a platform to evaluate recruitment 
interventions simultaneously across many trials. 
Finally, where evidence does not yet exist, information about these gaps will be 
systematically directed to funding agencies for consideration in their prioritisation processes. 
In the meantime, Trial Forge will provide a repository for experience and knowledge from 
the community of trialists, trial managers, and others about interventions and approaches that 
they believed worked well in their settings. Trial Forge will thus provide support for 
electronically linked communities of practice (for example, through question and answer and 
discussion sections on its website) to facilitate sharing of knowledge and experiences, 
especially when rigorous evidence to inform decisions is lacking. 
Step 4 - Collaborate to work through the methodology research agenda 
A methodology research agenda will have been created in Step 3. Step 4 will encourage wide 
collaboration among methodologists, trialists, and other relevant stakeholders to tackle this 
research agenda. For some processes in the trial pathway (Fig. 1), the agenda will be 
substantial and very challenging. A single research group or trials unit is unlikely to have the 
skills, capacity, or interest to take on a whole agenda. By bringing research groups together 
around a shared agenda, Trial Forge will minimise unnecessary duplication, focus work on 
topics shown to be most in need of attention (with a recent survey of the priorities of UK 
Clinical Trials Unit Directors providing a good starting point [48]), and identify groups with 
the necessary expertise to do the work. For example, groups could work together to evaluate 
an intervention described in a SWAT. This collaboration between groups may happen 
naturally through direct contact but could be facilitated by Trial Forge, for example by having 
a coordinator identify potential links and encouraging collaboration. 
Step 5 - Dissemination 
The value of the expanded evidence base will be realised in Step 5: when Trial Forge has 
identified or generated an important result from, for example, an up-to-date systematic review 
of relevant methodology research, people who need to know about it should be informed 
efficiently. For example, if, as a result of including new trial data to the Cochrane review of 
interventions to improve retention in trials [8] meant that there was now clear evidence that a 
particular intervention was effective, Trial Forge would help to ensure that this information is 
disseminated efficiently to trialists. A variety of dissemination routes will be used, for 
example, electronic mailing lists, a Twitter feed, presentations at the UK Clinical Trials Units 
Directors’ meetings and training courses. Dissemination routes are likely to need to change 
over time and may well need to differ depending on the trial process being addressed. An 
underlying principle will be that simply publishing the findings in a journal article is unlikely 
to be sufficient to promote uptake. To maximise the impact of this methodology research, 
Trial Forge will use evidence from implementation research to promote clinical and 
professional behaviour change interventions [49]. This step of Trial Forge will also be 
evaluated. 
The five steps in Trial Forge will be iterative, especially since many trial processes are linked 
and because suggestions for change in one area may have consequences for others. Trial 
Forge’s own processes will also be evaluated and modified over time as we and others learn 
from our experience of using the five steps to reduce gaps in knowledge about how best to 
design, conduct, analyse, and report trials. Once started, Trial Forge should produce a steady 
stream of methodology innovations that address trial process problems of recognised 
significance to people involved in trials. Importantly, work, and prestige will not be 
concentrated in one place or group but will be distributed across a collaborative network. 
Groups engaging with Trial Forge will be encouraged to build up their own portfolios of 
methodology work in areas that match their interests and expertise. 
Conclusion 
Trial Forge aims to support active and regular engagement with people who design, conduct, 
analyse, and report trials in the UK and elsewhere. It will promote meaningful improvements 
in trial efficiency and greater potential for trials to improve health. Moreover, Trial Forge will 
support an informal network of interested trialists, who will meet virtually and occasionally 
in person to build capacity and knowledge in efficient trials design and conduct. It will aim to 
be the ‘go to’ website for summaries of what is known about trial methods research but also 
for a linked programme of applied methodology research that encourages people to 
collaborate to fill gaps in evidence. 
Not all problems in trials need more methodology research. However, many aspects of trial 
design, conduct, analysis, and reporting could be subjected to research to identify the relative 
effects of alternative approaches and whether these aspects are scientific, methodological, or 
administrative; they all have uncertainties that could be addressed by research leading to 
greater evidence-based approaches than is currently the case. We believe that Trial Forge will 
maximise the effectiveness and efficiency of trials, increase the chances that they will 
produce reliable and robust answers, and minimise waste. Trialists share many of the same 
problems; Trial Forge is about working together to solve them. 
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